Evidence map›Paper›PMID 31901718›Full record

ArticleJournal of the neurological sciences2020

Neurophysiologic and ophthalmic markers of chemotherapy-related cognitive impairment in patients diagnosed with hematologic cancer: A feasibility study.

David E Anderson, Sachin Kedar, Vijaya R Bhatt, Kendra Schmid, Sarah A Holstein, Matthew Rizzo

Open access · greenAbstract read
In one paragraph

Article in Journal of the neurological sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

David E AndersonDepartment of Neurological Sciences, College of Medicine, University of Nebraska Medical Center (UNMC), USA; Fred & Pamela Buffett Cancer Center, UNMC, USA; Department of Ophthalmology & Visual Sciences, UNMC, USA; Stanley M. Truhlsen Eye Institute, USA. Electronic address: david.anderson@unmc.edu.
Sachin KedarDepartment of Neurological Sciences, College of Medicine, University of Nebraska Medical Center (UNMC), USA; Department of Ophthalmology & Visual Sciences, UNMC, USA; Stanley M. Truhlsen Eye Institute, USA.
Vijaya R BhattFred & Pamela Buffett Cancer Center, UNMC, USA; Division of Oncology & Hematology, Department of Internal Medicine, UNMC, USA.
Kendra SchmidDepartment of Biostatistics, College of Public Health, UNMC, USA.
Sarah A HolsteinFred & Pamela Buffett Cancer Center, UNMC, USA; Division of Oncology & Hematology, Department of Internal Medicine, UNMC, USA.
Matthew RizzoDepartment of Neurological Sciences, College of Medicine, University of Nebraska Medical Center (UNMC), USA; Fred & Pamela Buffett Cancer Center, UNMC, USA.
Susan Thompson Buffett Foundation · USUniversity of Nebraska Medical Center · US

Funding

UNMC/EPPLEY CANCER CENTER SUPPORT GRANTP30CA036727 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Joann B. Sweasy · 1985 to 2026
$55.0M
Tracking and Evaluation CoreU54GM115458 · NIGMS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI HOLSTEIN, SARAH A · 2016 to 2025
$42.8M
PREDICTIONS OF DRIVER SAFETY IN ADVANCING AGER01AG017177 · NIA · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI RIZZO, MATTHEW · 1999 to 2024
$9.9M
NCI NIH HHS P30 CA036727NIA NIH HHS R01 AG017177NIGMS NIH HHS U54 GM115458
6 · The paper itself

Abstract

backgroundBiomarkers of chemotherapy-related cognitive impairment (CRCI) in hematologic cancer are understudied and underdeveloped. We evaluated the feasibility of using ophthalmic and neurophysiologic markers to assess CRCI in hematologic cancer.

methodsHematologic cancer patients either receiving (Ctx+) or not receiving (Ctx-) chemotherapy were recruited from a tertiary medical center. Demographically-matched healthy controls (HC) were also recruited. Ctx+ participants completed the following study visits: (1) after diagnosis but prior to chemotherapy (baseline); (2) after one treatment cycle (one-month post-baseline); and (3) after three treatment cycles (three-months post-baseline). Comparison subjects completed assessments at similar intervals. Participants completed: (1) neuropsychological assessments of attention and executive function; (2) neurophysiologic assessments of control over spatial attention and working memory; and (3) ophthalmic assessments of contrast sensitivity and optical coherence tomography (OCT).

resultsWe enrolled 45 participants (15 per group), and 30 participants (Ctx+ = 8; Ctx- = 10; HC = 12) completed all study visits. Ctx+ participants performed worse than HC participants on neuropsychological measures of attention and executive function. Both Ctx+ and Ctx- participants showed changes in neurophysiologic measures of control over spatial attention that differed from HC participants. Ctx+ participants showed chemotherapy-related declines in contrast sensitivity that were predicted by OCT retinal nerve fiber layer thickness (RNFL) changes. Changes in neurophysiologic measures of control over spatial attention were also predicted by OCT RNFL changes.

conclusionWe demonstrated the feasibility of using ophthalmic and neurophysiologic markers as rapid and non-invasive measures that may be useful for tracking CRCI in hematologic cancer.

Indexed as

Chemotherapy-Related Cognitive ImpairmentHematologic NeoplasmsFeasibility StudiesHumansNeuropsychological TestsTomography, Optical CoherenceCancerChemotherapyCognitionContrast sensitivityEEGOCT

Identifiers

PMID31901718
PMCPMC7043069
OpenAlexW2997091707

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.